Side-by-side · Research reference
ARA 290vsPEG-MGF
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BAnimal-MechanisticHUMAN-REVIEWED2/69 cited
PEG-MGF
IGF-1Ec Splice Variant · PEGylated
~2 hrHalf-life (PEG)
~7 minNative MGF t½
IGF-1EcSplice variant
SQ · Research Protocol
01Mechanism of Action
Parameter
ARA 290
PEG-MGF
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
IGF-1 receptor on muscle satellite cells and myocytes
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Satellite cell activation, muscle fiber repair, localized hypertrophy signaling
Feedback intact?
N/A — does not interact with hematopoietic EPO receptorLiu 2014
Partially bypassed — does not require hepatic IGF-1 synthesis
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation
Antibody development
Not reported in clinical trials
Unknown — no long-term human immunogenicity data
02Dosage Protocols
Parameter
ARA 290
PEG-MGF
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
Post-training or daily
Timing to match endogenous MGF pulse post-exercise.
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
Animal / mechanistic
Timing
Any time of day
No circadian dependence reported.
Within 30–60 min post-training
Aligns with endogenous MGF window.
Research dose range
—
100–200 mcg
Extrapolated from animal models; no validated human protocols.
Half-life
—
~2 hours (PEGylated)
Native MGF: ~7 min; PEGylation extends circulation.
Reconstitution
—
Sterile bacteriostatic water
Lyophilized form; store reconstituted at 2–8 °C.
PEG molecular weight
—
Typically 5–30 kDa
Higher MW = longer t½, greater steric hindrance.
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
PEG-MGF
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
Lean mass preservation / hypertrophy focus
Primary target
—
Muscle tissue (satellite cells, myocytes) — not adipose-specific
Indirect metabolic effect
—
IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015
Mechanism distinct from direct lipolytic peptides.
Fat loss evidence
—
No direct human or animal RCT data for PEG-MGF-driven fat reduction
04Side Effects & Safety
Parameter
ARA 290
PEG-MGF
Injection site reaction
Mild, transient
Erythema, induration (common with SQ peptides)
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Hypoglycemia risk
—
IGF-1 axis activation can lower blood glucose
IGF-1R overstimulation
—
Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure
Fluid retention
—
Possible with IGF-1 pathway activation (dose-dependent)
PEG accumulation
—
Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment
Antibody formation
—
PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)
Cancer risk
—
IGF-1 axis stimulation contraindicated in active malignancy
Human safety data
—
Absent — no published human trials for PEG-MGF
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
PEG-MGF
- ·Active malignancy or history of cancer (IGF-1R proliferative signaling)
- ·Known hypersensitivity to PEGylated compounds
- ·Pregnancy / lactation (no reproductive toxicity data)
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
PEG-MGF
- ·Diabetes (monitor glucose closely)
- ·Renal impairment (PEG clearance reduced)
- ·Retinopathy (IGF-1 axis effects on vascular proliferation)
05Administration Protocol
Parameter
ARA 290
PEG-MGF
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
PEG-MGF
+ BPC-157
ModerateBPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.
- PEG-MGF
- 100–200 mcg SQ post-training
- BPC-157
- 250–500 mcg SQ or oral, twice daily
- Duration
- 4–6 weeks (injury-dependent)
- Primary benefit
- Accelerated muscle and connective tissue repair, enhanced recovery
+ TB-500
StrongTB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.
- PEG-MGF
- 100–200 mcg SQ post-training
- TB-500
- 2–5 mg SQ, 2× per week (loading), then weekly
- Timing
- Stagger injections by 6–12 hours
- Primary benefit
- Maximal satellite cell recruitment and myogenic differentiation, injury repair